A Phase 2 interventional study of Alpha-1 Antitrypsin and Placebo in New Onset Type-1 Diabetes, sponsored by Kamada, Ltd.. Completed at 4 sites in Israel. Open to participants aged 8 Years to 25 Years. Per ClinicalTrials.gov, last updated 2018-10-11.
Sponsored by Kamada, Ltd. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 189 studies in Diabetes Mellitus with a site in Israel — 9 open to participants now, 12 under way, 2 of them phase 3. Diabetes Mellitus · Israel.
Among the 189 studies in Diabetes Mellitus with a site in Israel, this one is the 99th largest by enrollment of the 145 interventional ones that give a count, is one of 7 that started in 2014, is one of 16 in phase 2, and was the 112th registered.
8,293 studies on the registry are indexed under Diabetes Mellitus; 1,072 are open to participants now.
Browse Diabetes Mellitus studies →9 of the 189 studies in Diabetes Mellitus with a site in Israel are open now. Recruiting first, the newest first:
Mapi Pharma Ltd. · Sites in Israel
Ages 18–64
Medtronic MiniMed, Inc. · Sites in Israel, Belgium, Denmark and 1 more country
Ages 2+
Western Galilee Hospital-Nahariya · Sites in Israel
Ages 18+ · Healthy volunteers
CSL Behring · Sites in Israel, United States, Argentina and 32 more countries
Ages 18+
Rabin Medical Center · Sites in Israel
Ages 2–45 · Healthy volunteers
A study can be open while its sites in Israel have not opened yet or have stopped. Only those recruiting at a site in Israel →
Of the 648 Diabetes Mellitus studies recruiting now, 357 (55%) set no upper age limit and 195 (30%) stop at 75 or younger; 88 take children under 18; 182 take healthy volunteers.
This study: 8 Years to 25 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
189 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 25 · Phase 3 60 · Phase 4 17
First in 1994; this study’s year is marked. 7 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 70 is below the median of 80 across 6,025 interventional studies indexed under Diabetes Mellitus.
Median enrollment 199 across the 145 interventional studies, 260 across the 43 observational. Of the 131 that completed or were terminated, 61 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
108 of 189 have an industry lead sponsor. The 10 most frequent:
Kamada, Ltd. is the lead sponsor of 11 studies on the registry; none are open to participants now.
Kamada, Ltd. has 1 study filed under Diabetes Mellitus — fewer than ten, so there is no comparison to draw.
1 of the studies in Diabetes Mellitus with a site in Israel that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07227805Medtronic MiniMed, Inc.Evaluation of the Safety and Performance of the Novel Medtronic Experimental Automated Insulin Delivery System (NMX8) in People Living With Diabetes (NEXUS) | 2027-03-17 |
Add it to your calendar (.ics) → With an account.
Among the 189 studies in Diabetes Mellitus with a site in Israel, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A Phase II, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Study Evaluating the Efficacy and Safety of Human, Alpha-1 Antitrypsin (AAT) [Glassia®] in the Treatment of New Onset Type-1 Diabetes.
The study objectives are:
Main Inclusion Criteria:
Main Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
60 mg/kg body weight
Biological: Alpha-1 Antitrypsin
120 mg/kg body weight
Biological: Alpha-1 Antitrypsin
Placebo
Other: Placebo
Also known as: Humman Alpha-1 Antitrypsin, Alpha-1 Proteinase Inhibitor, API, AAT
Placebo
Beta cell function
Beta cell function (measured by C peptide)
Time frame: 12 months from baseline
Glycemic control
Glycemic control expressed in HbA1c level
Time frame: 12 months from baseline
Beta cell function
Time frame: 12 months from baseline
Insulin dose
Time frame: 12 months from baseline
Hypoglycemic episodes
Time frame: 12 months from baseline
Safety parameters
Adverse events, vital signs, physical examination
Time frame: 12 months from baseline
The record gives a start of Apr 2014, a primary completion of Feb 2017 and a completion of Feb 2017. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Alpha 1-Antitrypsin
Kamada, Ltd.